ArticleJournal of the American Heart Association2025
Nuclear Receptor Subfamily 4 Group A Member 1 Exacerbates Cardiac Remodeling by Inhibiting Mitochondrial Function Through the Peroxisome Proliferator-Activated Receptor γ Coactivator-1α/Nuclear Respiratory Factor 1/Transcription Factor A Mitochondrial Axis.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure is characterized by cardiac dysfunction, cardiac remodeling, and mitochondrial dysfunction. NR4a1 (nuclear receptor subfamily 4 group A member 1) plays a crucial role in regulating mitochondrial function and biological performance in various diseases. The main objective of this study was to investigate the influence of NR4a1 on cardiac hypertrophy and uncover its underlying mechanism.
methodsA mouse model was established by transverse aortic constriction surgery, and an in vitro model was established by phenylephrine-treated neonatal rat ventricular myocytes. Mice were transfected with adeno-associated virus 9 to assess the role of NR4a1 in cardiac hypertrophy. We used PGC1α (peroxisome proliferator-activated receptor γ coactivator-1α) cardiac-specific knockout mice for subsequent experiments to investigate the impact of NR4a1 on mitochondrial bioenergetics.
resultsNR4a1 overexpression significantly exacerbates transverse aortic constriction-induced cardiac remodeling and cardiac dysfunction, and NR4a1 knockdown attenuates cardiac remodeling and cardiac dysfunction. Mechanistically, NR4a1 modulated cardiac remodeling and heart failure by impairing mitochondrial bioenergetics through PGC1α/NRF1 (nuclear respiratory factor 1)/TFAM (transcription factor A mitochondrial) axis. Inhibition of PGC1α activation is critical for NR4a1 to impair mitochondrial bioenergetics in cardiac hypertrophy. Furthermore, cardiac-specific PGC1α knockdown counteracts heart failure and mitochondrial dysfunction ameliorated by NR4a1 knockdown.
conclusionsCollectively, our findings demonstrate that NR4a1 drives pathological cardiac remodeling and heart failure progression by suppressing the PGC1α/NRF1/TFAM axis, leading to impaired mitochondrial function. Targeting NR4a1 and its interactions with PGC1α may hold promise for the development of novel therapeutic strategies for treating cardiac hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.